Acute duodenal Crohn's disease successfully managed with low-speed elemental diet infusion via nasogastric tube: a case report.

Duodenal Crohn's disease is rare, and patients without obstruction are treated medically. We herein report one case whose duodenal Crohn's disease was successfully managed with low-speed elemental diet infusion through a nasogastric tube. A 28-year-old female developed acute duodenal Crohn's disease. Upper GI radiologic and endoscopic examinations showed a stricture in the duodenal bulb. Using the duodenal biopsy specimens, mucosal cytokine levels were measured; interleukin (IL)-1beta, IL-6, IL-8, and tumor necrosis factor-alpha levels were remarkably elevated. For initial 2 wk, powdered mesalazine was orally given but it was not effective. For the next 2 wk, she was treated with low-speed elemental diet therapy using a commercially available Elental(TM), which was infused continuously through a nasogastric tube using an infusion pump. The tip of the nasogastric tube was placed at an immediate oral side of the pylorus. The infusion speed was 10 mL/h (usual speed, 100 mL/h). After the 2-wk treatment, her symptoms were very much improved, and endoscopically, the duodenal stricture and inflammation improved. The duodenal mucosal cytokine levels remarkably decreased compared with those before the treatment. Although our experience was limited, low-speed elemental diet infusion through a nasogastric tube may be a useful treatment for acute duodenal Crohn's disease.

[1]  M. Nakahigashi,et al.  Impact of Elemental Diet on Mucosal Inflammation in Patients with Active Crohn's Disease: Cytokine Production and Endoscopic and Histological Findings , 2005, Inflammatory bowel diseases.

[2]  J. Fell,et al.  Mucosal healing and a fall in mucosal pro‐inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease , 2000, Alimentary pharmacology & therapeutics.

[3]  M. Keighley,et al.  An audit of gastroduodenal Crohn disease: clinicopathologic features and management. , 1999, Scandinavian journal of gastroenterology.

[4]  J. Walker-Smith,et al.  The effect of treatment on lymphokine‐secreting cells in the intestinal mucosa of children with Crohn's disease , 1995, Alimentary pharmacology & therapeutics.

[5]  R. Macdermott,et al.  Enhand secretion of tumour necrosis factor‐alpha, IL‐6, and IL‐1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease , 1993 .

[6]  S. Schreiber,et al.  Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. , 1993, Clinical and experimental immunology.

[7]  R. Ma,et al.  Duodenal Crohn's disease: an analysis of 89 cases. , 1989, The American journal of gastroenterology.

[8]  R. Farmer,et al.  Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. , 1985, Gastroenterology.